![](/img/cover-not-exists.png)
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
Dent, Rebecca A, Lindeman, Geoffrey J, Clemons, Mark, Wildiers, Hans, Chan, Arlene, McCarthy, Nicole J, Singer, Christian F, Lowe, Elizabeth S, Watkins, Claire L, Carmichael, JamesVolume:
15
Language:
english
Journal:
Breast Cancer Research
DOI:
10.1186/bcr3484
Date:
October, 2013
File:
PDF, 207 KB
english, 2013